PA8594601A1 - Nueva modificacion cristalina de la 2-(3,5-bis-trifluormetil-fenil)-n[6-(1,1-dioxo126 -tiomorfolin-4-il)4(4-flour-2-metil-fenil)-piridin-3-il]-n-metil-isobutiramida - Google Patents
Nueva modificacion cristalina de la 2-(3,5-bis-trifluormetil-fenil)-n[6-(1,1-dioxo126 -tiomorfolin-4-il)4(4-flour-2-metil-fenil)-piridin-3-il]-n-metil-isobutiramidaInfo
- Publication number
- PA8594601A1 PA8594601A1 PA20048594601A PA8594601A PA8594601A1 PA 8594601 A1 PA8594601 A1 PA 8594601A1 PA 20048594601 A PA20048594601 A PA 20048594601A PA 8594601 A PA8594601 A PA 8594601A PA 8594601 A1 PA8594601 A1 PA 8594601A1
- Authority
- PA
- Panama
- Prior art keywords
- methyl
- phenyl
- isobutiramide
- tiomorfolin
- piridin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Detergent Compositions (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A UNA NUEVA MODIFICACION CRISTALINA DE LA 2-(3,5-BIS-TRIFLUORMETIL-FENIL)-N-[6-(1,1-DIOXO-126-TIOMORFOLIN-4-IL)-4-(4-FLUOR-2-METIL-FENIL)-PIRIDIN-3-IL]-N-METIL-ISOBUTIRAMIDA, CARACTERIZADA POR EL SIGUIENTE MODELO DE DIFRACCION POR RAYOS X, OBTENIDO CON UNA RADIACION CUKA A 2? (2TETA)= 4,5, 6,4, 7,5, 7,7, 8,0, 8,2, 10,0, 10,2, 10,9, 11,1, 12,9, 13,4, 14,0, 14,5, 15,1, 15,6, 16,2, 16,5, 17,3, 17,5, 18,0, 18,9, 19,3, 19,5, 19,9, 20,1, 20,6, 21,0, 21,4, 22,7, 23,1 Y 23,6 Y UN ESPECTRO DE INFRARROJOS CON BANDAS AGUDAS A 2925, 2854, 1637, 1604, 1484, 1395, 1375, 1285, 1230, 1172, 1125, 1082, 999, 943, 893, 868, 860, 782, 705, 684 cm-1, Y EN DONDE EL PUNTO DE FUSION EXTRAPOLADO (DSC) ES DE 137,2ºC.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03002134 | 2003-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8594601A1 true PA8594601A1 (es) | 2004-09-16 |
Family
ID=32798734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20048594601A PA8594601A1 (es) | 2003-01-31 | 2004-01-28 | Nueva modificacion cristalina de la 2-(3,5-bis-trifluormetil-fenil)-n[6-(1,1-dioxo126 -tiomorfolin-4-il)4(4-flour-2-metil-fenil)-piridin-3-il]-n-metil-isobutiramida |
Country Status (28)
Country | Link |
---|---|
US (1) | US7160881B2 (es) |
EP (1) | EP1592428B1 (es) |
JP (1) | JP5026702B2 (es) |
KR (1) | KR100700421B1 (es) |
CN (1) | CN100562320C (es) |
AR (1) | AR042980A1 (es) |
AT (1) | ATE366576T1 (es) |
AU (1) | AU2004208483B8 (es) |
BR (1) | BRPI0406702A (es) |
CA (1) | CA2514037C (es) |
CL (1) | CL2004000150A1 (es) |
CO (1) | CO5580750A2 (es) |
DE (1) | DE602004007486T2 (es) |
ES (1) | ES2290666T3 (es) |
GT (1) | GT200400009A (es) |
HR (1) | HRP20050664A2 (es) |
IL (1) | IL169600A (es) |
MX (1) | MXPA05008171A (es) |
MY (1) | MY135785A (es) |
NO (1) | NO20053431L (es) |
NZ (1) | NZ541243A (es) |
PA (1) | PA8594601A1 (es) |
PE (1) | PE20040944A1 (es) |
PL (1) | PL378404A1 (es) |
RU (1) | RU2330022C2 (es) |
TW (1) | TWI293294B (es) |
WO (1) | WO2004067007A1 (es) |
ZA (1) | ZA200505567B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4580426B2 (ja) | 2004-07-06 | 2010-11-10 | エフ.ホフマン−ラ ロシュ アーゲー | Nk−1受容体拮抗薬の合成において中間体として使用されるカルボキサミド誘導体の製造方法 |
KR20070094666A (ko) | 2005-02-25 | 2007-09-20 | 에프. 호프만-라 로슈 아게 | 약제 물질 분산성이 향상된 정제 |
MX2012002369A (es) * | 2009-08-27 | 2012-03-29 | Glaxosmithkline Llc | Formas de anhidrato de un derivado de piridina. |
CN103755592A (zh) * | 2013-12-30 | 2014-04-30 | 镇江圣安医药有限公司 | (2z)-氰基-3-羟基-n-[4-(三氟甲基)苯基]-2-丁烯酰胺的衍生物及其应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
CA2178219C (en) | 1993-12-29 | 2005-03-22 | Raymond Baker | Substituted morpholine derivatives and their use as therapeutic agents |
IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
US5972938A (en) * | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
SE1035115T5 (sv) | 1999-02-24 | 2015-08-04 | Hoffmann La Roche | 4-fenylpyridin-derivat och deras anvaendning som NK-1 receptor-antagonister |
AU2002250876B2 (en) * | 2001-04-23 | 2005-03-03 | F. Hoffmann-La Roche Ag | Use of NK-1 receptor antagonists against benign prostatic hyperplasia |
US6849624B2 (en) * | 2001-07-31 | 2005-02-01 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted amides |
-
2004
- 2004-01-23 MX MXPA05008171A patent/MXPA05008171A/es active IP Right Grant
- 2004-01-23 BR BR0406702-9A patent/BRPI0406702A/pt not_active Application Discontinuation
- 2004-01-23 PL PL378404A patent/PL378404A1/pl unknown
- 2004-01-23 JP JP2005518353A patent/JP5026702B2/ja not_active Expired - Fee Related
- 2004-01-23 RU RU2005127216/04A patent/RU2330022C2/ru not_active IP Right Cessation
- 2004-01-23 ES ES04704575T patent/ES2290666T3/es not_active Expired - Lifetime
- 2004-01-23 WO PCT/EP2004/000547 patent/WO2004067007A1/en active IP Right Grant
- 2004-01-23 KR KR1020057014025A patent/KR100700421B1/ko not_active IP Right Cessation
- 2004-01-23 CA CA2514037A patent/CA2514037C/en not_active Expired - Fee Related
- 2004-01-23 AU AU2004208483A patent/AU2004208483B8/en not_active Ceased
- 2004-01-23 CN CN200480003306.7A patent/CN100562320C/zh not_active Expired - Fee Related
- 2004-01-23 EP EP04704575A patent/EP1592428B1/en not_active Expired - Lifetime
- 2004-01-23 AT AT04704575T patent/ATE366576T1/de active
- 2004-01-23 DE DE602004007486T patent/DE602004007486T2/de not_active Expired - Lifetime
- 2004-01-23 NZ NZ541243A patent/NZ541243A/en unknown
- 2004-01-27 US US10/766,122 patent/US7160881B2/en not_active Expired - Fee Related
- 2004-01-27 TW TW093101746A patent/TWI293294B/zh active
- 2004-01-28 PA PA20048594601A patent/PA8594601A1/es unknown
- 2004-01-28 PE PE2004000110A patent/PE20040944A1/es not_active Application Discontinuation
- 2004-01-29 GT GT200400009A patent/GT200400009A/es unknown
- 2004-01-30 CL CL200400150A patent/CL2004000150A1/es unknown
- 2004-01-30 MY MYPI20040288A patent/MY135785A/en unknown
- 2004-01-30 AR ARP040100284A patent/AR042980A1/es unknown
-
2005
- 2005-07-07 IL IL169600A patent/IL169600A/en unknown
- 2005-07-11 ZA ZA200505567A patent/ZA200505567B/en unknown
- 2005-07-14 NO NO20053431A patent/NO20053431L/no not_active Application Discontinuation
- 2005-07-18 CO CO05070753A patent/CO5580750A2/es not_active Application Discontinuation
- 2005-07-21 HR HR20050664A patent/HRP20050664A2/xx not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200510453A (en) | Crystalline polypeptides | |
DE60329237D1 (de) | Kristalline form von linezolid | |
EA200301115A1 (ru) | Кристаллические формы азитромицина | |
RS93604A (en) | Substituted phenylacetamides and their use as glucokinase activators | |
CY1112906T1 (el) | Αναστολεις διαυλου νατριου | |
CO5550395A2 (es) | Antranilamidas artropodicidas | |
CY1113578T1 (el) | 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια | |
EA200401345A1 (ru) | Лечение гастропареза | |
AP2005003261A0 (en) | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors. | |
EA200200819A1 (ru) | Кристаллическая форма ii линезолида | |
WO2006055964A3 (en) | Zolmitriptan crystal forms | |
EA200501226A1 (ru) | Новая кристаллическая модификация негидратированного боскалида | |
TW200738145A (en) | Pesticidal mixtures | |
PA8594601A1 (es) | Nueva modificacion cristalina de la 2-(3,5-bis-trifluormetil-fenil)-n[6-(1,1-dioxo126 -tiomorfolin-4-il)4(4-flour-2-metil-fenil)-piridin-3-il]-n-metil-isobutiramida | |
SI1532131T1 (sl) | Motilidne spojine | |
ATE457982T1 (de) | Thiazol-(bi)cycloalkyl-carboxanilide | |
DE602004015794D1 (de) | Metalloxid-formulierungen | |
TW200735779A (en) | Pesticidal mixtures | |
NO20055582L (no) | Preparater og fremgangsmater omfattende gastrinforbindelser | |
DE60215918D1 (de) | Azofarbstoffe | |
DOP2004000808A (es) | Nueva modificacion cristalina de la 2-(3,5-bis-trifluormetilfenil)-n-[6-(1,1-dioxo-1 6-tiomorfolin-4-il)-4-(4-fluor-2-metil-fenil)-piridin-3-il]-n-metil-isobutiramida | |
AU2003265109A1 (en) | The supporter of fishing rod | |
DE60320304D1 (de) | Kristallstruktur von menschlichem il-18 | |
DE60214397D1 (en) | 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza-cyclopenta(a)naphthalenyl derivate mit antipsychotischer aktivität | |
ATE338759T1 (de) | 2-(aminomethyl)tetrahydro-9-oxa-1,3- diazacyclopentaca)naphthalinylderivate mit antipsychotischer wirkung |